Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier

This study is currently recruiting participants.
Verified August 2012 by Capital District Health Authority, Canada
Sponsor:
Information provided by (Responsible Party):
Richard Hall, Capital District Health Authority, Canada
ClinicalTrials.gov Identifier:
NCT00878371
First received: April 7, 2009
Last updated: August 2, 2012
Last verified: August 2012

April 7, 2009
August 2, 2012
May 2009
December 2012   (final data collection date for primary outcome measure)
The primary outcome variables are the correlation between the ratio of CSF/plasma morphine , morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) levels and the plasma concentration of IL-6 over time. [ Time Frame: CSF and Blood samples will be taken in the OR, post operatively ( every 6 hrs until POD 5 if CSF drain still in place) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00878371 on ClinicalTrials.gov Archive Site
  • Correlation between CSF/Plasma ratios of morphine, M3G, M6G and plasma concentration of TNFα and ET-1 over time. [ Time Frame: CSF and Blood samples will be taken in the OR, post operatively ( every 6 hrs until POD 5 if CSF drain still in place) ] [ Designated as safety issue: No ]
  • Correlation between CSF/plasma ratios for morphine, M3G, M6G and CSF/Plasma ratios for albumin and S-100β over time. [ Time Frame: CSF and Blood samples will be taken in the OR, post operatively ( every 6 hrs until POD 5 if CSF drain still in place) ] [ Designated as safety issue: No ]
Same as current
 
 
 
Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier
Identification and Quantification of the Effects of a Surgery-induced Peripheral Inflammatory Response on Changes in Drug Efflux Transporter Function in the Brain

The purpose for this study is to determine if surgery (repair of descending thoracic aneurysm) causes a temporary decrease in the Blood Brain Barrier's ability to remove drugs from the brain back into the blood. The Blood Brain Barrier surrounds the brain and the spinal cord. This Blood Brain Barrier acts as a filter and allows some things to cross into the brain and allows other matter to be removed. Studies have shown the Blood Brain Barrier is affected by inflammation.

Functions of the Blood Brain Barrier in animals have been studied. Human studies with multiple causes of inflammation (e.g. Alzheimer's, Epilepsy, trauma and severe infections in critically

Hypothesis: Surgically-induced inflammation will temporarily reduce blood-brain barrier drug efflux transporter function in proportion to the degree of inflammation. The investigators anticipate that inflammation-mediated reductions in drug transporter function will be reflected by an increased cerebral spinal fluid (CSF) concentration of morphine (a PGP substrate) and M3G and M6G (MRP1 substrates). The corresponding in vitro studies will allow us to elucidate the mechanism(s) by which inflammation alters blood brain barrier efflux transport of morphine, M3G and M6G.

Study Objectives: To determine the role of surgery-induced inflammation on the transport of morphine and its metabolites, M3G and M6G, across the blood-brain barrier.

Study phase: IV Study Design: This is a sequential enrolment study design in which elective surgical patients presenting for repair of an ascending thoracic aneurysm and fitted with a CSF drain as part of their standard of care will be approached for permission to draw blood samples at specified times during their hospital course. Concomitantly, samples of CSF will be collected from the CSF drainage system (CSF is normally wasted).

Morphine will be used as the primary analgesic agent (this is within the standard of care). Samples will be collected at specified time intervals for 5 days or until the CSF drain is removed (whichever comes first). Samples collected will be analysed for morphine, its 3- and 6- glucuronide metabolites, inflammatory cytokines, markers of CNS injury and anatomical integrity of the BBB. Area under the concentration vs. time curve will be calculated and the effect on morphine metabolism and penetration across the BBB will be determined using a repeated measures analysis of variance technique (as used in our previous study).

Interventional
Phase 4
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Dissecting Aneurysm of the Thoracic Aorta
Procedure: Repair of descending thoracic aneurysm and morphine
Elective surgical patients undergoing repair of a descending thoracic aortic aneurysm, requiring insertion of a cerebral spinal fluid (CSF) drain and receiving Morphine as their primary analgesic agent can be enrolled
 
Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1245-64. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subjects who are to undergo elective surgery for thoracic aortic vascular disease requiring insertion of a lumbar CSF drain
  2. Informed consent will be obtained from the subject or authorized legal representative -

Exclusion Criteria:

  1. Unwilling or unable to provide informed consent
  2. Sensitivity or documented allergy to morphine
  3. Inability to place lumbar CSF drain
  4. Dialysis dependent -
Both
 
No
Contact: Richard I Hall, MD 902-473-2328 rihall@dal.ca
Contact: Lisa C Julien, RN BScN CCRP 902-473-7883 lisa.julien@cdha.nshealth.ca
Canada
 
NCT00878371
Hall Morphine TAA-01
No
Richard Hall, Capital District Health Authority, Canada
Capital District Health Authority, Canada
 
Principal Investigator: Richard I Hall, MD Capital Health- Queen Elizabeth II Health Sciences Center
Capital District Health Authority, Canada
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP